Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

NCT ID: NCT00373841

Last Updated: 2025-10-29

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2030-07-31

Brief Summary

The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.

Detailed Description

People who are diagnosed with idiopathic pulmonary fibrosis are asked to participate in this study. The subject must be treated at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease. Subjects, if consented, are required to perform tests so that research data can be collected. At the initial visit, patients are subject to having a blood draw, pulmonary function testing, echocardiograms, and CT scans as well as completing several questionnaires designed to measure how the patient is feeling. Follow up visits are then scheduled in 3-4 month intervals. Every 3-4 months blood samples will be collected while every 6-8 months the questionnaires will administered. If the patient enters a stage of accelerated decline in lung function, a bronchoscopy will be performed to collect residual bronchoalveolar lavage fluid for testing. All of the results of clinical and laboratory testing will be placed into the subjects research file.

Conditions

Idiopathic Pulmonary Fibrosis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Eligibility Criteria

Inclusion Criteria

• Patients who are 18 or older
• Diagnosis of Idiopathic Pulmonary Fibrosis
• Treated at the Simmons Center

Exclusion Criteria

• Other Lung Illness

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Pittsburgh

OTHER

Sponsor Role: lead

Responsible Party

Kevin F. Gibson

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kevin F Gibson, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh - Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease

Locations

Michelle F MacPherson

Pittsburgh, Pennsylvania, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Michelle MacPherson, MAT

Role: CONTACT

macphersonmj@upmc.edu

412-647-4537

Michelle Meyers, BSN RN

Role: CONTACT

meyersma@upmc.edu

412-692-2149

Facility Contacts

Michelle F MacPherson, MAT

Role: primary

macphersonmj@upmc.edu

14126474537

Michelle L Meyers, BSN RN

Role: backup

meyersma@upmc.edu

412-692-2149

References

Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014 May;43(5):1430-8. doi: 10.1183/09031936.00141013. Epub 2013 Oct 31.

Reference Type: DERIVED

PMID: 24177001 (View on PubMed)

Related Links

http://www.upmc.com/services/pulmonology/interstitial-lung-disease/

Homepage for the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease

Other Identifiers

STUDY19040326

Identifier Type: -

Identifier Source: org_study_id